March 2, 2011 – Despite a long-standing requirement for medical device makers to include women in studies they submit to the U.S. Food and Drug Administration (FDA) for approval, only a few include enough or analyze how the devices work specifically in women, according to research in Circulation: Cardiovascular Quality and Outcomes.

March 2, 2011 – A new transseptal puncture module for education and simulation technology has been released. The module is for Simbionix’ Angio Mentor simulator.

March 2, 2011 – The Society for Cardiovascular Angiography and Interventions (SCAI) announced recommendations for assessing and improving the quality at percutaneous coronary intervention (PCI) programs at cardiac facilities.

March 2, 2011 – America’s hospitals and health systems are focusing more on renovation or expansion than new construction, according to a survey from Health Facilities Management magazine and the American Society for Healthcare Engineering (ASHE). In fact, renovation or expansion accounted for 73 percent of construction projects at hospitals responding to the survey.

March 1, 2011 – Medtronic, St. Jude Medical and Biotronik have emerged as leaders in the €2.8 billion European cardiac rhythm management (CRM) electrophysiology and ablation market, according to iData Research. The companies have been particularly successful in the telehealth monitoring for cardiac implantable electric devices (CIEDs).

March 1, 2011 – A bioprosthetic heart valve has demonstrated positive performance at 12 years, according to a study published in The Journal of Thoracic and Cardiovascular Surgery. The Mosaic heart valve, from Medtronic, was evaluated in patients who had aortic valve replacement (AVR) and mitral valve replacement (MVR).

March 1, 2011 – The U.S. Food and Drug Administration (FDA) approved azilsartan medoxomil to treat high blood pressure (hypertension) in adults. Azilsartan medoxomil, also known as Edarbi, is made by Takeda Pharmaceutical North America.

March 1, 2011 – A new study assessing the utility of genetic testing to determine a personalized warfarin dose for individual patients has begun at Overlake Hospital Medical Center in Bellevue, Wash. The WARFARIN Study will help determine if genetic testing can reduce a patient’s risk of serious bleeding or clotting events. It will use a test developed by Iverson Genetic Diagnostics.

February 28, 2011 – Scientists have identified a protein that plays a key role in debilitating changes that occur in the heart after a heart attack, according to research reported in Circulation Research: Journal of the American Heart Association.

February 28, 2011 – At the National Institutes of Health (NIH) summit on managing radiation dose in computerized tomography, representatives from the American College of Radiology (ACR) outlined strategies for transforming computed tomography (CT) technology and minimizing radiation exposure.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now